Securities ▲▼ | Shares | Value | |||||
|---|---|---|---|---|---|---|---|
Q1 2026 ▲▼ | Q2 2026 ▲▼ | Change ▲▼ | Q1 2026 ▲▼ | Q2 2026 ▲▼ | Weight (%) ▲▼ | Change ▲▼ | |
| CG Oncology, Inc.(CGON) | 6,371,669 | 6,371,669 | 0 | $431.23M | $452.71M | 61.87% | +$21.47M |
| Nuvation Bio Inc.(NUVB) | 25,954,439 | 25,954,439 | 0 | $111.34M | $147.42M | 20.15% | +$36.08M |
| AARDVARK THERAPEUTICS INC | 3,917,299 | 3,917,299 | 0 | $14.77M | $22.56M | 3.08% | +$7.80M |
| Aclaris Therapeutics, Inc. | 4,041,736 | 4,041,736 | 0 | $15.16M | $21.38M | 2.92% | +$6.22M |
| Upstream Bio Inc. | 2,724,868 | 2,724,868 | 0 | $24.52M | $18.86M | 2.58% | -$5.67M |
| Arcus Biosciences, Inc.(RCUS) | 477,819 | 464,779 | -13,040 | $10.32M | $14.33M | 1.96% | +$4.01M |
| Equillium Inc. | 4,447,308 | 4,447,308 | 0 | $8.89M | $14.23M | 1.94% | +$5.34M |
| Revolution Medicines, Inc.(RVMD) | 93,500 | 52,667 | -40,833 | $9.09M | $9.86M | 1.35% | +$770.6K |
| Lyell Immunopharma, Inc. | 692,050 | 692,050 | 0 | $13.88M | $9.72M | 1.33% | -$4.16M |
| BeyondSpring Inc. | 3,800,702 | 3,800,702 | 0 | $6.23M | $6.65M | 0.91% | +$418.1K |
| Zentalis Pharmaceuticals Inc. | 1,323,327 | 1,323,327 | 0 | $3.10M | $6.42M | 0.88% | +$3.32M |
| NEWAMSTERDAM PHARMA CO NV ORDINARY SHARES | 325,057 | 176,887 | -148,170 | $10.41M | $5.99M | 0.82% | -$4.41M |
| Pyxis Oncology, Inc (formerly Apexigen) | 326,810 | 326,810 | 0 | $477.1K | $983.7K | 0.13% | +$506.6K |
| Tango Therapeutics, Inc.(TNGX) | 0 | 20,000 | +20,000 | $0 | $625.2K | 0.09% | +$625.2K |
| Krystal Biotech, Inc.(KRYS) | 7,300 | 0 | -7,300 | $1.89M | $0 | — | -$1.89M |